Press coverage about STAAR Surgical (NASDAQ:STAA) has trended somewhat positive on Saturday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. STAAR Surgical earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned media coverage about the medical instruments supplier an impact score of 44.1873163740917 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Several brokerages have recently issued reports on STAA. Zacks Investment Research cut shares of STAAR Surgical from a “hold” rating to a “sell” rating in a research note on Friday. BidaskClub raised shares of STAAR Surgical from a “strong sell” rating to a “sell” rating in a research note on Tuesday, January 16th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company. STAAR Surgical currently has a consensus rating of “Hold” and a consensus target price of $17.67.
Shares of NASDAQ STAA traded down $0.60 during trading on Friday, hitting $14.10. 118,206 shares of the company traded hands, compared to its average volume of 91,087. STAAR Surgical has a 1 year low of $8.95 and a 1 year high of $17.60. The stock has a market capitalization of $608.84, a PE ratio of 1,410.00 and a beta of 1.26. The company has a quick ratio of 2.13, a current ratio of 2.82 and a debt-to-equity ratio of 0.01.
STAAR Surgical (NASDAQ:STAA) last announced its quarterly earnings data on Wednesday, February 28th. The medical instruments supplier reported $0.02 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.03 by ($0.01). STAAR Surgical had a negative net margin of 2.36% and a negative return on equity of 2.28%. The company had revenue of $24.85 million for the quarter. equities research analysts expect that STAAR Surgical will post 0.03 EPS for the current fiscal year.
In related news, CTO Keith Holliday sold 2,188 shares of the company’s stock in a transaction on Thursday, March 22nd. The shares were sold at an average price of $16.03, for a total transaction of $35,073.64. Following the completion of the sale, the chief technology officer now directly owns 43,781 shares of the company’s stock, valued at approximately $701,809.43. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Caren L. Mason sold 6,667 shares of the company’s stock in a transaction on Monday, March 19th. The stock was sold at an average price of $16.09, for a total transaction of $107,272.03. Following the sale, the chief executive officer now directly owns 51,513 shares of the company’s stock, valued at $828,844.17. The disclosure for this sale can be found here. Insiders have sold a total of 13,479 shares of company stock valued at $216,561 over the last three months. Corporate insiders own 5.60% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/04/07/staar-surgical-staa-getting-somewhat-positive-news-coverage-study-finds.html.
About STAAR Surgical
STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery.
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.